Organovo Holdings (ONVO): Debt to Book Capitalization Ratio

Corporate company logo of Organovo Holdings (ONVO)

Organovo Holdings, Inc. (ONVO) creates living liver tissues for transplantation, leveraging high-demand 3D bioprinting. Diversification through the development of metabolic drugs and partnerships with pharmaceutical behemoths minimizes risks. The debt-to-capitalization ratio on the GURU.Markets temporary chart demonstrates financial stability, where the value 3.39 reflects the metric's balance. However, slow commercialization of technologies limits market confidence regarding payback periods.

ONVO Organovo Corp: Debt to Book Value in the range 07/04/2022 - 04/24/2025
Manufactured products of Organovo Holdings Inc

Organovo Holdings, Inc. (ONVO) is developing complex biomaterial delivery chains for 3D bioprinting that require high operational resilience. This indicator compares total liabilities with the current market value of equity. Investors utilize this tool to assess the debt load relative to market expectations. Analyzing the company's debt-to-equity ratio helps determine the business's financial flexibility. The dynamics of this metric reflect the issuer's ability to fund logistics without the risk of bankruptcy.

Competitor analysis

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|Debts to Book Capitalization madrigalpharma.com MDGL|CORT - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio RYTM (Rhythm Pharma)|Akero Therapeutics Inc (AKRO) - Debt to Book Capitalization Ratio|Debt to Book Value Metsera Therapeutics|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com|Debt to Book Value NAMS (NewAmsterdam Pharma Company N.V.)|SLNO (Soleno Therapeutics Inc) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Amicus Pharma FOLD|ETNB - Debt to Book Value|Agios Pharmaceuticals - Debts to Book Capitalization|Debts to Book Value structuretx.com|MDXG (MiMedx) - Debt to Book Value|RZLT: Debt to Book Capital|LXRX (Lexicon Pharma) - Debts to Book Capitalization|Debts to Book Capitalization MBX Corp|Debts to Book Capitalization ALT|Debt to Book Capitalization Ratio AARD (aardvarktherapeutics.com)|Debt to Book Capitalization Ratio Sagimet Biosciences Inc. SGMT|BioAge Labs (BIOA) - Debts to Book Value|BMEA - Debt to Book Capitalization Ratio|QNCX: Debt to Book Capitalization Ratio|GUTS: Debts to Book Capitalization|VTVT - Debts to Net Assets|Debt to Book Capitalization Ratio Agape ATP Corp|Pluri Inc (PLUR) - Debts to Net Assets|Debt to Book Capitalization Ratio Synlogic, Inc. (SYBX)|Debt to Book Value Lipocine Corporation LPCN|Debt to Book Capitalization Ratio Matinas BioPharma Holdings MTNB|Spruce Biosciences Inc. (SPRB) - Debts to Book Value|GLTO - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio CTCX (Carmell Corp.)|LUMO: Debts to Book Capitalization|Debt to Net Assets Radius Pharmaceuticals RDUS